Murray Norris

26PUBLICATIONS
170CO-AUTHORS
Molecular targetsMedical molecular engineering of nucleic acids and proteinsCancer geneticsHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Nov 28, 2025
Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma.

Jeremy Z R Han, Monica Phimmachanh, Jordan F Hastings

|Jun 02, 2025
The cell-permeable iron chelator M606 inhibits MYCN-driven neuroblastoma via an E2F3-mediated response.

Ruby Pandher, Chengyuan Xue, Laura D Gamble

|Feb 21, 2025
The polyamine transporter ATP13A3 mediates difluoromethylornithine-induced polyamine uptake in neuroblastoma.

Mujahid Azfar, Weiman Gao, Chris Van den Haute

|Jul 11, 2024
The transcriptional co-repressor Runx1t1 is essential for MYCN-driven neuroblastoma tumorigenesis.

Jayne E Murray, Emanuele Valli, Giorgio Milazzo

|Apr 05, 2024
Loss of the stress sensor GADD45A promotes stem cell activity and ferroptosis resistance in LGR4/HOXA9-dependent AML.

Nunki Hassan, Hangyu Yi, Bilal Malik

|Jan 10, 2024
Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan for patients with relapsed neuroblastoma: a New Approaches to Neuroblastoma Therapy trial.

Michael D Hogarty, David S Ziegler, Andrea Franson

Pageof 5

Frequent Collaborators

18 joint publications

Michelle Haber

14 joint publications

Chelsea Mayoh

9 joint publications

Jamie I Fletcher

7 joint publications

Toby N Trahair